Solid Biosciences (SLDB)
NASDAQ:SLDB
Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$8.63
$0.18(4.59%)
At close: 4:00 PM EST
$8.63
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.41 - $8.87
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.41M
Market Cap
$701.55M
Enterprise Value$523.33M
Total Cash (Recent Filing)$189.07M
Total Debt (Recent Filing)$21.16M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 07, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding98,394,720
10 Day Avg. Volume1,011,322
30 Day Avg. Volume1,409,109
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-415.34
Enterprise Value/Ebitda-3.04
Forecast
1Y Price Target
$17.75Price Target Upside105.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySGT-003 shows consistent micro-dystrophin protein expression across patients and evidence of muscle preservation and cardiac improvements, supporting a potential disease-modifying effect.
Regulatory PathwayPlanned engagement with the regulator and alignment on a confirmatory trial increase the chance of pursuing an accelerated approval pathway and reduce regulatory uncertainty.
Safety And Treatment BurdenA favorable safety profile with most adverse events resolving and a low-burden steroid-only immunomodulation regimen makes the therapy more attractive to patients and clinicians.
Bears Say
Analyst Conflict Of InterestDisclosed business relationships and expected investment banking compensation create potential conflicts of interest that could undermine perceived objectivity of analyst reports.
Financial RunwayOngoing operating losses and lack of product revenue necessitate additional external financing, raising dilution and execution risk for clinical programs.
Variability In ResponseA subset of earlier patients experienced suboptimal micro-dystrophin expression, indicating variability in individual response that could complicate regulatory or commercial outcomes.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.41 and its highest was $8.87 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $701.55M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Mar 19, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.519 by -$0.011.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.43.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 98,394,720 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.519. Following the earnings report the stock price went down -1.264%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (105.68% Upside)
$17.75 (105.68% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 211.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $809.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
238.43%
12-Months-Change
Fundamentals
Return on Equity
-73.34%
Trailing 12-Months
Asset Growth
23.26%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$17.75
▲(105.68% Upside)
Technical Analysis
Ownership Overview
13.16% Insiders
9.35% Mutual Funds
0.48% Other Institutional Investors
69.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---